Of 4 patients who developed metachronous ovarian metastases, 2 had the BRAF V600E mutation, 1 had the KRAS mutation and 1 had the wild types of both genes in the primary tumour (the patients who had the wild types of both genes in the primary tumour demonstrated the KRAS mutation in the ovarian metastasis). This evidence concerns the gene BRAF and neoplasm.